ConductScience.org, home

Paper42444693

2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity.

Huong TTL and 13 others. RSC Adv, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. 2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity. Papers, record 42444693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42444693

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity.
PubMed
Journal
RSC Adv
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-14
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huong TTLTran Thi Lan
2Kim HKHwa Kyung
3Thai NANguyen Anh
4Anh DPDong Phuong
5Thao NTPNguyen Thi Phuong
6Ngan NPNguyen Phuong
7Thang NQNguyen Quoc
8Kang DHDa Hyeon
9Kim HYHa Young
10Kang JSJong Soon
11Anh DTDuong Tien
12Tung TTTruong Thanhhttps://orcid.org/0000-0002-5263-203X
13Han SBSang-Bae
14Nam NHNguyen-Haihttps://orcid.org/0000-0001-8475-2530

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126133355Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.Med Chem2015https://conductscience.org/library/papers/26133355PubMed
28744570VMD: visual molecular dynamics.J Mol Graph1996https://conductscience.org/library/papers/8744570PubMed
317962618FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.Oncologist2007https://conductscience.org/library/papers/17962618PubMed
428196602Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.Bioorg Chem2017https://conductscience.org/library/papers/28196602PubMed
537122176Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors.J Enzyme Inhib Med Chem2023https://conductscience.org/library/papers/37122176PubMed
627573798Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification.Sci Rep2016https://conductscience.org/library/papers/27573798PubMed
725738536Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Molecules2015https://conductscience.org/library/papers/25738536PubMed
811052792Prediction of drug absorption using multivariate statistics.J Med Chem2000https://conductscience.org/library/papers/11052792PubMed
928177238Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity.J Med Chem2017https://conductscience.org/library/papers/28177238PubMed
1035887396Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors.Int J Mol Sci2022https://conductscience.org/library/papers/35887396PubMed
1116397526Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.Nat Rev Cancer2006https://conductscience.org/library/papers/16397526PubMed
1212036371Molecular properties that influence the oral bioavailability of drug candidates.J Med Chem2002https://conductscience.org/library/papers/12036371PubMed
1312429021Histone deacetylases (HDACs): characterization of the classical HDAC family.Biochem J2003https://conductscience.org/library/papers/12429021PubMed
1410490031Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.Nature1999https://conductscience.org/library/papers/10490031PubMed
1533266366Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).Int J Mol Sci2020https://conductscience.org/library/papers/33266366PubMed
1627318122Inside HDACs with more selective HDAC inhibitors.Eur J Med Chem2016https://conductscience.org/library/papers/27318122PubMed
1737404064Novel hydrazone-isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling.Arch Pharm (Weinheim)2023https://conductscience.org/library/papers/37404064PubMed
1817694074HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.Oncogene2007https://conductscience.org/library/papers/17694074PubMed
1937805934AmberTools.J Chem Inf Model2023https://conductscience.org/library/papers/37805934PubMed
2024185378Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.Eur J Med Chem2013https://conductscience.org/library/papers/24185378PubMed

See all 41 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
HDAC99734PubTator's text mininghttps://conductscience.org/library/genes/9734

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42444693

GET https://conductscience.org/api/papers/v1/42444693/references?page=2